Clinical trial · NCT02302482
Predictive Factors and Autonomy Level Change
Sponsor: Hospices Civils de Lyon
Summary
The Alzheimer's disease or related disorders (ADRD) are among the most disabling diseases because of their main features such as cognitive impairment, loss of functional autonomy and behavioural disorders. In absence of current curative treatment, the identification of the predictive risk factors of progression of the disease, evaluated through its main symptoms, represents a major stake of public health. The investigators aimed at developing a database, which includes the patient medical records on a prospective basis, in collaboration with the medical and administrative personal and with the University hospital computer science department. The main objective is to study the predictive factors associated with the change of functional autonomy level, measured every 6 months to 12 months by phone, in a Memory Clinic. The study population would consist in about 1000 patients with ADRD. The length of follow-up of each patient will be 3 years.
Interventions
- The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6 · OTHER
Published eligibility criteria
Verbatim from the registry. Only the site can decide how these apply to a specific patient.
Inclusion Criteria: * Patients who undergo a medical visit in the Memory Clinic for the 1st time * Patients living at home or in housing * Patients with memory impairment, at all stage of the disease Exclusion Criteria: * Patients in institution * Patients under legal protection * Patients with a hearing or visual impairment, which dot not allow to carry out the examination
Sites (2)
- Hôpital Dugoujon, Caluire-et-Cuire, France · Not yet recruiting
- Hospices Civils de Lyon - Hôpital des Charpennes, Lyon, France · Recruiting
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2021-06-28.